CABA

Cabaletta Bio (CABA)

Cabaletta Bio Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CABA

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/14	19 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CABA	Cabaletta Bio Inc
2024/06/14	15 : 00	GlobeNewswire Inc.	Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201	NASDAQ:CABA	Cabaletta Bio Inc
2024/06/05	08 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CABA	Cabaletta Bio Inc
2024/06/05	08 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CABA	Cabaletta Bio Inc
2024/06/05	05 : 32	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CABA	Cabaletta Bio Inc
2024/05/29	21 : 00	GlobeNewswire Inc.	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference	NASDAQ:CABA	Cabaletta Bio Inc
2024/05/15	20 : 53	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CABA	Cabaletta Bio Inc
2024/05/15	20 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CABA	Cabaletta Bio Inc
2024/05/15	20 : 00	GlobeNewswire Inc.	Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:CABA	Cabaletta Bio Inc
2024/05/13	21 : 00	GlobeNewswire Inc.	Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	NASDAQ:CABA	Cabaletta Bio Inc
2024/03/21	20 : 00	GlobeNewswire Inc.	Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:CABA	Cabaletta Bio Inc
2024/03/20	20 : 00	GlobeNewswire Inc.	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	NASDAQ:CABA	Cabaletta Bio Inc
2024/03/05	07 : 50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CABA	Cabaletta Bio Inc
2024/03/05	07 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CABA	Cabaletta Bio Inc
2024/03/05	07 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CABA	Cabaletta Bio Inc
2024/03/05	07 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CABA	Cabaletta Bio Inc
2024/03/05	07 : 28	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CABA	Cabaletta Bio Inc
2024/02/27	22 : 00	GlobeNewswire Inc.	Cabaletta Bio to Participate in Upcoming Investor Conferences in March	NASDAQ:CABA	Cabaletta Bio Inc
2024/02/14	23 : 20	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:CABA	Cabaletta Bio Inc
2024/02/14	08 : 47	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:CABA	Cabaletta Bio Inc
2024/02/02	06 : 36	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CABA	Cabaletta Bio Inc
2024/02/02	06 : 30	GlobeNewswire Inc.	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis	NASDAQ:CABA	Cabaletta Bio Inc
2024/01/31	22 : 00	GlobeNewswire Inc.	Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	NASDAQ:CABA	Cabaletta Bio Inc
2024/01/20	08 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CABA	Cabaletta Bio Inc
2024/01/08	21 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CABA	Cabaletta Bio Inc
2024/01/08	21 : 00	GlobeNewswire Inc.	Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	NASDAQ:CABA	Cabaletta Bio Inc
2024/01/02	22 : 00	GlobeNewswire Inc.	Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:CABA	Cabaletta Bio Inc
2023/12/20	10 : 37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CABA	Cabaletta Bio Inc
2023/11/29	20 : 18	IH Market News	Amazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and More	NASDAQ:CABA	Cabaletta Bio Inc
2023/11/29	06 : 30	GlobeNewswire Inc.	Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference	NASDAQ:CABA	Cabaletta Bio Inc